Table 1.
Experimental dengue virus vaccines
| Type | Sponsor | Stage of Development |
|---|---|---|
| Live attenuated | ||
| Tetravalent | Mahidol University/Sanofi Pasteur | Phase I |
| Tetravalent | WRAIR/GSK | Phase II |
| Chimeric | ||
| ChimeriVax (17D YF) | Acambis/Sanofi Pasteur | Phase I |
| DENV-2/4d30 (all serotypes) | NIAID, NIH | Phase I/II |
| DENV-1 | US FDA | Phase I |
| DENV-2 (16,681, PDK53) | CDC/Inviragen | Preclinical |
| DNA | ||
| Several approaches | Various | |
| (ie, Domain III, prM/E, NS1) | NMRC/University of Pittsburgh | Phase I/Preclinical |
| Inactivated | ||
| Several approaches | WRAIR | Preclinical |
| Subvirion particles/viruslike particles | ||
| Drosophila cells | Hawaii Biotech | Phase I |
| Baculovirus (E, NS1) | Various | Preclinical |
| Replication-defective AV (E) | RepliVax-UTMB/Acambis | Preclinical |
| Yeast (C/prM/E, E-IIBsAg) | Various | Preclinical |
| Escherichia coli (E, E-NS1) | Various | Preclinical |
| DNA | University of Pittsburgh | Preclinical |
| Subunit/recombinant | Various | Preclinical |
Abbreviations: AV, adenovirus; CDC, Centers for Disease Control and Prevention; GSK, GlaxoSmithKline; NIAID, National Institute of Allergy and Infectious Diseases; NIH, National Institutes of Health; UTMB, University of Texas Medical Branch; WRAIR, Walter Reed Army Institute of Research; YF, yellow fever.